Nifedipine
Nifedipine, Procardia (nifedipine) is a small molecule pharmaceutical. Nifedipine was first approved as Procardia on 1982-01-01. It is used to treat hypertension, stable angina, and variant angina pectoris in the USA. It is known to target voltage-dependent L-type calcium channel subunit alpha-1F, glycine receptor subunit alpha-3, voltage-gated potassium channel KCNC1, voltage-dependent L-type calcium channel subunit alpha-1S, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 7, glycine receptor subunit beta, potassium voltage-gated channel subfamily A member 2, nuclear receptor subfamily 1 group I member 2, transient receptor potential cation channel subfamily M member 3, voltage-dependent L-type calcium channel subunit alpha-1C, voltage-dependent L-type calcium channel subunit alpha-1D, glycine receptor subunit alpha-1, and potassium voltage-gated channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Nifedipine, Procardia (discontinued: Adalat, Afeditab, Nifedipine, Procardia)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adalat cc | New Drug Application | 2014-05-14 |
| afeditab | ANDA | 2016-08-06 |
| nifediac cc | ANDA | 2010-06-07 |
| nifedical | ANDA | 2013-09-26 |
| nifedicalxl | ANDA | 2013-10-02 |
| nifedipine | ANDA | 2025-09-19 |
| nifedipine nifedipine | ANDA | 2011-01-11 |
| nifedipine er | ANDA | 2011-01-11 |
| procardia | New Drug Application | 2023-11-27 |
| procardia xl | New Drug Application | 2011-12-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| stable angina | — | D060050 | I20.89 |
| variant angina pectoris | — | D000788 | I20.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB03: Atenolol and nifedipine
— C08: Calcium channel blockers
— C08C: Selective calcium channel blockers with mainly vascular effects
— C08CA: Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
— C08CA05: Nifedipine
— C08CA55: Nifedipine, combinations
— C08G: Calcium channel blockers and diuretics
— C08GA: Calcium channel blockers and diuretics
— C08GA01: Nifedipine and diuretics
HCPCS
No data
Clinical
Clinical Trials
186 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 7 | 10 | 34 | 20 | 72 |
| Premature obstetric labor | D007752 | — | O60 | 2 | 6 | 8 | 5 | 10 | 28 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 4 | 6 | 5 | 9 | 23 |
| Pregnancy-induced hypertension | D046110 | — | O13 | 2 | 2 | 2 | 12 | 5 | 22 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 3 | 2 | 2 | 9 | 7 | 21 |
| Essential hypertension | D000075222 | — | I10 | 2 | 1 | 5 | 5 | 3 | 16 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 2 | 1 | 1 | 4 | 9 |
| Fissure in ano | D005401 | — | K60.2 | 2 | 5 | 3 | 1 | — | 6 |
| Hyperaldosteronism | D006929 | — | E26 | — | — | — | 2 | 3 | 5 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | — | — | 2 | 2 | 4 |
Show 29 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proteinuria | D011507 | — | R80 | 2 | 3 | 1 | — | — | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 3 | 4 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | 1 | — | 2 | 3 |
| Toxemia | D014115 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | 2 | — | — | 3 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 2 | — | — | 2 |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | 1 | 1 | — | — | 2 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 2 | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | 1 | — | — | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | — | 2 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | 2 | 2 | — | — | 4 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | 2 | 3 |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | — | 1 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | 1 | — | — | 1 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | 1 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 2 | — | — | — | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | 1 | — | — | — | 1 |
| Embryo implantation | D010064 | — | — | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | — | — | 2 | 3 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | — | — | — | 2 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 3 | — | — | — | — | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Pregnancy complications | D011248 | — | — | 1 | — | — | — | — | 1 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | 1 | — | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Edema | D004487 | — | R60.9 | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 2 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
| Hypokalemia | D007008 | — | E87.6 | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
Show 80 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nifedipine |
| INN | nifedipine |
| Description | Nifedipine is a dihydropyridine, a methyl ester and a C-nitro compound. It has a role as a calcium channel blocker, a vasodilator agent, a tocolytic agent and a human metabolite. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-] |
Identifiers
| PDB | — |
| CAS-ID | 21829-25-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL193 |
| ChEBI ID | 7565 |
| PubChem CID | 4485 |
| DrugBank | DB01115 |
| UNII ID | I9ZF7L6G2L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
KCNC1
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily C member 1
Protein synonyms
NGK2, potassium channel, voltage gated Shaw related subfamily C, member 1, voltage-gated potassium channel protein KV3.1, Voltage-gated potassium channel subunit Kv3.1, Voltage-gated potassium channel subunit Kv4
Uniprot ID
Mouse ortholog
Kcnc1 (16502)
potassium voltage-gated channel subfamily C member 1 (P15388)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nifedipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,222 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nifedipine nifedipine, Nifedipine er
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,658 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use